NDRG4 methylation change, a promising biomarker in colorectal cancer diagnosis
Archives of Advances in Biosciences,
Vol. 11 No. 4 (2020),
28 Azar 2020
,
Page 23-28
https://doi.org/10.22037/aab.v11i4.31058
Abstract
Background: Colorectal cancer (CRC) is the third common type of cancer with rising prevalence worldwide. Despite the diagnoses and treatments developed over the past four decades, the survival rate of patients has improved somewhat, but still has a 5-year survival rate of less than 50%. In this study hypermethylation of NDRG4 gene was evaluated as a biomarker in screening of CRC.
Method: A total of 70 individuals enrolled in this case-control study (45 CRC patients vs. 25 normal controls) and Methylation-Specific PCR was used to evaluate methylation status of NDRG4 in plasma samples.
Result: Mean age in the control group and CRC patients was 58.4±3.4 years and 64.6±4.4 years respectively. Male to female ratio in the control group and CRC patients was 1.5:1 and 1.1:1 respectively. Gastrointestinal disease history was positive in 12% and 33% of patients in the control group and CRC patients respectively. 53.3% of CRC patients showed hypermethylation in NDRG4 gene vs. only 23.3% of controls.
Conclusion: The results showed that NDRG4 can be a promising biomarker in screening and diagnosis of CRC as a noninvasive blood-based biomarker.
- Colorectal cancer
- methylation
- screening
- NDRG4
How to Cite
References
Chung RY-N, Tsoi KK, Kyaw MH, Lui AR, Lai FT, Sung JJ-Y. A population-based age-period-cohort study of colorectal cancer incidence comparing Asia against the West. Cancer epidemiology. 2019; 59:29-36.
Ma H, Brosens LA, Offerhaus GJA, Giardiello FM, de Leng WW, Montgomery EA. Pathology and genetics of hereditary colorectal cancer. Pathology. 2018; 50(1):49-59.
Pozsgai E, Busa C, Fodor D, Bellyei S, Csikos A. Wait times to diagnosis and treatment in patients with colorectal cancer in Hungary. Cancer epidemiology. 2019; 59:244-8.
Kojima M, Shimazaki H, Iwaya K, Nakamura T, Kawachi H, Ichikawa K, et al. Intramucosal colorectal carcinoma with invasion of the lamina propria: a study by the Japanese Society for Cancer of the Colon and Rectum. Human pathology. 2017; 66:230-7.
Weiser MR. Ajcc 8th edition: Colorectal cancer. Annals of surgical oncology. 2018; 25(6):1454-5.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians. 2017; 67(3):177-93.
Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide burden of colorectal cancer: a review. Updates in surgery. 2016; 68(1):7-11.
Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR, et al. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. The Journal of biological chemistry. 2009; 284(37):25160-9.
Okuda T, Kokame K, Miyata T. Differential expression patterns of NDRG family proteins in the central nervous system. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2008; 56(2):175-82.
Huang Z, Bassil CF, Murphy SK. Methylation-specific PCR. Methods in molecular biology. 2013; 1049:75-82.
Zhong X, Shen H, Mao J, Zhang J, Han W. Epigenetic silencing of protocadherin 10 in colorectal cancer. Oncology letters. 2017; 13(4):2449-53.
Su XL, Wang YF, Li SJ, Zhang F, Cui HW. High methylation of the SEPT9 gene in Chinese colorectal cancer patients. Genetics and molecular research: GMR. 2014; 13(2):2513-20.
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014; 63(2):317-25.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. The New England journal of medicine. 2014; 370(14):1287-97.
Wensheng Liu, Fei Yue, Minhua Zheng, Angelica Merlot, Bae D-H. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget Journal. 2015; 6(11):8851-74.
Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. Journal of the National Cancer Institute. 2009; 101(13):916-27.
Ashoori H, Ghamarchehreh ME, Tavallaei M, GANji SM, Hosseini M, Zolfaghari M, et al. Evaluation of the Epigenetic Biomarker Bone Morphogenic Protein 3 for Colorectal Cancer Diagnosis. Journal of Clinical & Diagnostic Research. 2018; 12(11).
Chung RY-N, Tsoi KK, Kyaw MH, Lui AR, Lai FT, Sung JJ-Y. A population-based age-period-cohort study of colorectal cancer incidence comparing Asia against the West. Cancer epidemiology. 2019; 59:29-36.
Ma H, Brosens LA, Offerhaus GJA, Giardiello FM, de Leng WW, Montgomery EA. Pathology and genetics of hereditary colorectal cancer. Pathology. 2018; 50(1):49-59.
Pozsgai E, Busa C, Fodor D, Bellyei S, Csikos A. Wait times to diagnosis and treatment in patients with colorectal cancer in Hungary. Cancer epidemiology. 2019; 59:244-8.
Kojima M, Shimazaki H, Iwaya K, Nakamura T, Kawachi H, Ichikawa K, et al. Intramucosal colorectal carcinoma with invasion of the lamina propria: a study by the Japanese Society for Cancer of the Colon and Rectum. Human pathology. 2017; 66:230-7.
Weiser MR. Ajcc 8th edition: Colorectal cancer. Annals of surgical oncology. 2018; 25(6):1454-5.
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA: a cancer journal for clinicians. 2017; 67(3):177-93.
Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi REM, Corcione F. Worldwide burden of colorectal cancer: a review. Updates in surgery. 2016; 68(1):7-11.
Schilling SH, Hjelmeland AB, Radiloff DR, Liu IM, Wakeman TP, Fielhauer JR, et al. NDRG4 is required for cell cycle progression and survival in glioblastoma cells. The Journal of biological chemistry. 2009; 284(37):25160-9.
Okuda T, Kokame K, Miyata T. Differential expression patterns of NDRG family proteins in the central nervous system. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2008; 56(2):175-82.
Huang Z, Bassil CF, Murphy SK. Methylation-specific PCR. Methods in molecular biology. 2013; 1049:75-82.
Zhong X, Shen H, Mao J, Zhang J, Han W. Epigenetic silencing of protocadherin 10 in colorectal cancer. Oncology letters. 2017; 13(4):2449-53.
Su XL, Wang YF, Li SJ, Zhang F, Cui HW. High methylation of the SEPT9 gene in Chinese colorectal cancer patients. Genetics and molecular research: GMR. 2014; 13(2):2513-20.
Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014; 63(2):317-25.
Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool DNA testing for colorectal-cancer screening. The New England journal of medicine. 2014; 370(14):1287-97.
Wensheng Liu, Fei Yue, Minhua Zheng, Angelica Merlot, Bae D-H. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1. Oncotarget Journal. 2015; 6(11):8851-74.
Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. Journal of the National Cancer Institute. 2009; 101(13):916-27.
Ashoori H, Ghamarchehreh ME, Tavallaei M, GANji SM, Hosseini M, Zolfaghari M, et al. Evaluation of the Epigenetic Biomarker Bone Morphogenic Protein 3 for Colorectal Cancer Diagnosis. Journal of Clinical & Diagnostic Research. 2018; 12(11).
- Abstract Viewed: 301 times
- PDF Downloaded: 277 times